HBV Treatment
EASL 2013: Do Asian Patients Respond Better to Pegylated Interferon for Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Wednesday, 08 May 2013 00:00
- Written by Liz Highleyman
Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at the EASL International Liver Congress(EASL 2013) last month in Amsterdam. The study also showed that early hepatitis B surface antigen (HBsAg) decline is a predictor of treatment response in some patients.
EASL 2013: Truvada Works Best for Immune-Tolerant Hepatitis B Patients -- But Do They Need Treatment?
- Details
- Category: HBV Treatment
- Published on Monday, 29 April 2013 00:00
- Written by Liz Highleyman
A combination of tenofovir and emtricitabine (the drugs in Truvada) suppressed hepatitis B virus (HBV) replication more than tenofovir alone over 4 years for people with inactive or immune-tolerant disease, researchers reported at the EASL International Liver Congress (EASL 2013) this week in Amsterdam. The benefits of treatment at this early stage, however, remain uncertain.
EASL 2013: Long-term Tenofovir Reduces Liver Cancer Risk in People with Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by Liz Highleyman
Long-term treatment with tenofovir (Viread) lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about 5 years, according to a report presented at the at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
Coverage of the 2013 EASL International Liver Congress
- Details
- Category: HBV Treatment
- Published on Saturday, 27 April 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.
4/27/13
EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights
- Details
- Category: HBV Treatment
- Published on Wednesday, 24 April 2013 00:00
- Written by Liz Highleyman
The EASL International Liver Congress is now underway at the Amsterdam RAI congress center. At a Wednesday press conference, EASL officials gave a preview of some of the hepatitis C treatment highlights -- both augmentation of interferon-based therapy and interferon-free regimens -- to be presented at the meeting, which runs through Sunday.
More Articles...
- Heavy Alcohol Use Increases Liver Cancer Risk in Hepatitis B Patients with Cirrhosis
- EASL International Liver Congress Starts this Week in Amsterdam
- CROI 2013: Dually Active Antiretroviral Therapy Protects Against Primary Hepatitis B Infection
- Antioxidant N-acetylcysteine Improves Survival of Transplanted Liver
Web Design and Development by